Inflammatory Bowel Disease (IBD), an umbrella term encompassing Crohn’s disease and ulcerative colitis, represents a significant global health challenge, affecting millions worldwide. Characterized by chronic inflammation of the gastrointestinal tract, IBD can manifest with debilitating symptoms ranging from severe abdominal pain and persistent diarrhea to weight loss and fatigue, profoundly impacting patients’ quality of life. While genetic predispositions and immune system dysregulation are recognized contributors, the role of environmental factors, particularly diet, in modulating disease activity and progression remains a complex area of ongoing investigation. Breakthrough research emanating from the UNC School of Medicine, recently published on August 13, 2026, in the esteemed journal Cellular and Molecular Gastroenterology and Hepatology (CMGH), sheds new light on a previously underestimated dietary component: oxalate. This investigation posits that for individuals living with IBD, naturally occurring oxalate, abundant in many otherwise nutritious plant-based foods, might actively exacerbate intestinal inflammation, challenging conventional dietary wisdom and opening novel therapeutic avenues.
The pioneering study, spearheaded by postdoctoral scholar Dr. Anna Salvador and conducted within the laboratory of Dr. Shehzad Z. Sheikh, a distinguished Professor of Medicine and Genetics, employed a multifaceted approach to unravel the intricate relationship between dietary oxalate and IBD pathology. Researchers meticulously analyzed gene expression profiles, measured oxalate concentrations in stool samples, and scrutinized dietary patterns across cohorts of IBD patients and healthy controls. Complementing these human observations, a series of in-depth experiments utilizing murine models and cultured cellular systems further elucidated the potential mechanisms by which dietary oxalate could influence the inflammatory cascade within the intestinal lining.
Oxalate, or oxalic acid, is an organic compound found naturally in virtually all plant-based foods, albeit in varying concentrations. Common dietary sources include leafy greens like spinach, nuts such as almonds, and starchy vegetables like sweet potatoes – foods frequently lauded for their health benefits. In a healthy digestive system, the vast majority of dietary oxalate ingested typically traverses the gastrointestinal tract without significant absorption and is subsequently excreted in the stool. This process relies on a delicate balance of absorption and transport mechanisms within the gut. However, the UNC team’s findings suggest that this crucial balance is fundamentally disrupted in individuals afflicted with IBD.
A cornerstone of the research revealed a consistent reduction in the expression levels of two specific transporter proteins, SLC26A2 and SLC26A3, within the intestinal tissue of patients diagnosed with either ulcerative colitis or Crohn’s disease. These proteins play a vital role in facilitating the movement of oxalate out of the intestinal lumen and into the bloodstream for eventual excretion by the kidneys. Intriguingly, this diminished presence of transporters was observed across affected intestinal segments irrespective of whether active inflammation was overtly present. Furthermore, the study established a direct correlation: as the degree of tissue inflammation intensified, the expression of these critical transporters tended to decline proportionally. This impairment in the gut’s oxalate transport machinery leads to a diminished capacity for dietary oxalate absorption, consequently leaving a greater concentration of the compound lingering within the intestinal environment. The novel hypothesis emerging from this research is that this elevated luminal oxalate may then act as a potent amplifier, intensifying the inflammatory responses already characteristic of IBD.
One of the most compelling pieces of evidence emerged from the analysis of patient cohorts, specifically involving individuals with Crohn’s disease. Despite consuming comparable quantities of plant-based foods as their healthy counterparts, Crohn’s patients exhibited significantly higher concentrations of oxalate in their stool samples. This striking observation was rigorously established through two distinct methodological approaches: the application of a validated dietary questionnaire (Diet History Questionnaire III) to assess food intake, and the innovative use of DNA metabarcoding, a sophisticated molecular technique capable of identifying specific plant species present in fecal matter. The researchers noted that this marked the inaugural application of DNA metabarcoding to evaluate dietary intake within an IBD patient population, underscoring the methodological novelty of their work. Dr. Salvador articulated the profound implication of this finding, stating that observing similar plant-food consumption yet elevated fecal oxalate in Crohn’s patients indicated a deeper issue beyond mere dietary intake. "It informed us that this isn’t solely about what patients consume," Dr. Salvador explained. "There’s a fundamental difference in how their gut processes oxalate." This outcome strongly suggests that an elevated oxalate burden within the intestines is driven less by the sheer quantity of oxalate consumed and more by an inherent biological dysfunction in the gut’s processing capabilities.
To further solidify the link between oxalate and intestinal inflammation, the research team transitioned to controlled experiments using various animal models. Mice subjected to an oxalate-supplemented diet, concurrently with a substance known to induce colitis, exhibited a significantly reduced survival rate – a striking 60 percent lower chance of survival – compared to mice that did not receive additional dietary oxalate. In two distinct murine models genetically predisposed to developing spontaneous colitis, the introduction of dietary oxalate accelerated the onset of the disease and markedly increased its severity. Critically, in these susceptible mouse strains, the genes responsible for oxalate transport were already less active before any oxalate supplementation was introduced into their diets, a pattern mirroring the observations made in human IBD patients. These animal findings provided robust in vivo evidence supporting the hypothesis that oxalate is not merely a passive bystander but an active participant in driving gut inflammation.
Beyond whole-organism studies, cellular culture experiments offered additional mechanistic clues. When immune cells, specifically macrophages and dendritic cells – critical components of the intestinal immune system responsible for protection and regulation – were exposed to oxalate, their inflammatory responses were demonstrably intensified. This direct interaction at the cellular level provides a granular understanding of how elevated oxalate within the intestinal environment could directly contribute to the chronic inflammatory state characteristic of IBD.
The research team also explored the potential for oxalate-related genetic markers to offer prognostic insights into the progression of Crohn’s disease. In an exploratory analysis, a diminished expression level of another specific transporter, SLC26A6, was found to be significantly associated with stricturing Crohn’s disease. This is a particularly aggressive manifestation of the condition where the repeated cycles of inflammation and healing lead to the formation of scar tissue, causing sections of the intestine to narrow, often necessitating surgical intervention. Nearly three-quarters (75 percent) of patients exhibiting low SLC26A6 expression were found to have this stricturing form of the disease. While this finding is preliminary and requires confirmation in larger patient cohorts, it raises an intriguing possibility: that monitoring oxalate transporter activity could eventually assist clinicians in identifying patients at an elevated risk of developing more severe disease phenotypes. Dr. Sheikh commended Dr. Salvador’s pivotal role, noting, "Dr. Salvador truly conceived and propelled this work from its genesis. She posed a question that had previously gone unasked: What if a specific dietary molecule actively drives gut inflammation in IBD, rather than merely being a concomitant factor? The rigorous methodology she applied to answer it renders these findings exceptionally compelling."
The profound implications of these findings for individuals managing IBD cannot be overstated, yet it is crucial to interpret them with precision. The study does not advocate for the wholesale elimination of nutrient-rich plant-based foods from the diets of IBD patients. Instead, the results suggest a more nuanced understanding: that in genetically susceptible individuals, even moderate quantities of oxalate, typically considered harmless, may contribute to the inflammation of the intestinal lining. The researchers also propose that previous studies investigating the interplay between diet and IBD may have been complicated by individual variations in how patients are exposed to or metabolize oxalate, a variable now brought to the forefront.
For those seeking to follow a nutritionally complete plant-based diet while simultaneously managing oxalate intake, strategies exist to achieve this balance. Furthermore, the burgeoning field of the gut microbiome offers another promising avenue for therapeutic intervention. Certain beneficial intestinal bacteria, notably Oxalobacter formigenes, possess the unique ability to metabolize and break down oxalate. Intriguingly, these oxalate-degrading bacteria are often found in reduced abundance in individuals with IBD. This observation opens the door to the exciting possibility that future microbiome-based treatments, such as targeted probiotics or fecal microbiota transplantation, could enhance oxalate degradation within the gut, thereby offering an alternative or complementary approach to relying solely on dietary restrictions.
Despite the compelling nature of this research, the investigators emphasize that these findings are not yet sufficient to warrant formal revisions to existing dietary guidelines for people with IBD. Future research endeavors are essential, requiring longitudinal studies that meticulously track larger patient cohorts over extended periods. These subsequent investigations will need to integrate multiple analytical layers, combining precise measurements of stool oxalate levels, thoroughly documented dietary intake records, comprehensive molecular profiling of gut tissues, and in-depth microbiome analyses. Dr. Sheikh underscored the transformative potential, stating, "For patients living with Crohn’s disease or ulcerative colitis, this research unveils a genuinely novel therapeutic perspective – one that directly links the food on their plate to the inflammation within their gut." He further articulated, "Diet stands as one of the most potent, modifiable levers at our disposal in medicine, and this study provides us with a molecular framework to begin employing it with greater precision."
This groundbreaking study received substantial financial backing from a consortium of distinguished organizations, including the Helmsley Charitable Trust, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the Chan Zuckerberg Initiative, Schmidt Sciences, the Burroughs Wellcome Fund, and additional sources from the National Institutes of Health. The collaborative spirit of this research is reflected in its authorship, spanning multiple institutions including UNC-Chapel Hill, Texas A&M University, and Duke University.
About the Author
